BSX Boston Scientific (BSX) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0000885725
Cluster · 5 insidersC-suite buying · 1Congress · 2
Funds added, last quarter
737
13F, latest reported quarter
Conversions, 180 days
3
Codes C/M, not in net · $0 priced
What the filings say about BSX
Insiders, 180 days
+$10.0M net bought
5 buyers
Congress, 1 year
2 bought · 3 sold
Latest: sale, 2026-09-09
Boston Scientific insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, BOSTON SCIENTIFIC CORP insiders bought a net $10.0M of stock across 218 Form 4 purchases and sales, with 5 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 14.8% of the 13,784 shares held after it.
- 3 other insiders bought within 30 days.
- 737 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Morano Susan E bought about $100.4K of BSX on Aug 25, 2026; 3 other insiders bought within 30 days and 737 funds added in the latest 13F quarter.Context
- 4 earlier Form 4 trades (code P or S) here by this insider (4 buys), the last on Aug 4, 2026.
- -10.2% median (-10.2% mean) 90-day return after 2 previous buys.
- The trade is 12.2% of the 17,160 shares held after it.
- 3 other insiders bought within 30 days.
- 737 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Habiger David C bought about $99.9K of BSX on Aug 5, 2026; 3 other insiders bought within 30 days and 737 funds added in the latest 13F quarter.Context
- 3 earlier Form 4 trades (code P or S) here by this insider (3 buys), the last on Aug 3, 2026.
- -10.2% median (-10.2% mean) 90-day return after 2 previous buys.
- The trade is 0.9% of the 15,060 shares held after it.
- 3 other insiders bought within 30 days.
- 737 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Habiger David C bought about $6.8K of BSX on Aug 4, 2026; 3 other insiders bought within 30 days and 737 funds added in the latest 13F quarter.Context
- 2 earlier Form 4 trades (code P or S) here by this insider (2 buys), the last on May 20, 2026.
- -10.2% median (-10.2% mean) 90-day return after 2 previous buys.
- The trade is 7.0% of the 14,920 shares held after it.
- 3 other insiders bought within 30 days.
- 737 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Habiger David C bought about $50.1K of BSX on Aug 3, 2026; 3 other insiders bought within 30 days and 737 funds added in the latest 13F quarter.Context
- 25 earlier Form 4 trades (code P or S) here by this insider (25 sales), the last on Feb 2, 2026.
- The trade is 11.7% of the 1,590,024 shares held after it.
- 3 other insiders bought within 30 days.
- 737 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, President & CEO Mahoney Michael F bought about $9.0M of BSX on Aug 3, 2026, the largest insider purchase at the company on our record; 3 other insiders bought within 30 days and 737 funds added in the latest 13F quarter.218 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$10.0M over 180 days
+$9.5M over 90 days
more than 98% of Medical Devices
Congress
2 members bought in the last year
more than 81% of Medical Devices
Funds
737 funds bought in last quarter
more than 98% of Medical Devices
Revenue
+19.9% year over year
more than 72% of Medical Devices
Margin
14.4% net margin
more than 87% of Medical Devices
Buybacks
$2.0B repurchased, FY to 2026-06-30
more than 95% of Medical Devices
Short interest
2.8% of the float short (float per yahoo 2026-10-27) · 2.6 days to cover · settled 2026-10-15
below 55% of Medical Devices
The situation: each line is one rule over one dataset
5 insiders independently bought a net $10.0M while the stock fell 23% over six months, with no planned sales queued.
6 trial completion dates slipped in the last 90 days.
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch BSX
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-56.0%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns BSX: institutional holders (13F)
13F holdings, latest reported quarter
129,680,916 sh
$5.5B
97,087,553 sh
$4.1B
70,111,196 sh
$3.0B
50,520,914 sh
$2.2B
45,702,845 sh
$2.0B
Congress trades in BSX
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-09 · disclosed 16 days later
$50,001 - $100,000
Sold 2026-09-04 · disclosed 21 days later
$50,001 - $100,000
Sold 2026-09-03 · disclosed 22 days later
$1,001 - $15,000
Sold 2026-08-31 · disclosed 25 days later
$15,001 - $50,000
Bought 2026-08-18 · disclosed 23 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
BSX planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
BSX mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Select Medical Technology and Devices Portfolio
$152.2M position · as of 2026-05-31
5.1%
iShares U.S. Medical Devices ETF
$120.6M position · as of 2026-06-30
4.0%
Goldman Sachs Future Health Care Equity ETF
$760.4K position · as of 2026-05-31
3.8%
First Trust Health Care AlphaDEX Fund
$26.0M position · as of 2026-07-31
2.5%
Global X Aging Population ETF
$2.0M position · as of 2026-05-31
2.4%
Harbor Health Care ETF
$989.1K position · as of 2026-07-31
2.4%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
187 registered trials, 71 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
1
Phase 1
1 active
2
Phase 2
1 active
5
Phase 3
2 active
2
Phase 4
1 active
177
Not applicable
66 active
What changed recently
Safety, Performance, and Clinical Benefit of Pacing the Left Bundle Branch Area - Post-M
2026-10-28 · Recruiting → Active Not Recruiting
,
Randomized Study on Transoral Outlet Reduction and Lifestyle Changes for Weight Regain A
2026-10-14 · Completion moved 2026-11 → 2027-07
Not applicable
Boston Scientific Registry of Deep Brain Stimulation for Treatment of Essential Tremor (
2026-10-14 · Completion moved 2029-12 → 2039-12
,
AXIOS™ Gastroenterostomy for Gastric Outlet Obstruction IDE
2026-10-08 · Completion moved 2027-08 → 2027-09
Not applicable
WATCHMAN FLX Pro European Registry
2026-10-01 · Recruiting → Active Not Recruiting
,
A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device
2026-09-29 · Completion moved 2026-10-31 → 2027-01-31
Phase 1
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Government contracts
Award ceilings over the contract's life, subsidiaries included.
Not annual revenue (USASpending.gov).
Department Of Veterans Affairs
THERASPHERE Y-90 GLASS MICROSPHERE MEDICATION · 2022-10-01
$3.8M
Federal awards ≥ $25M in the last 90 days, matched via the SAM.gov parent registry
Corporate PAC
The company's PAC: committee totals only, never individual donors (FEC).
Boston Scientific Corporation Political Action Committee (Bsc Pac)
Cycle 2026 · $326K spent
$341.5K
Federal Election Commission, matched by the PAC's connected organisation
Executive pay vs shareholder return · Michael F. Mahoney
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$23.5M
$33.0M
$5.8M
+165%
+48%
2024
$21.4M
$65.8M
$5.5M
+148%
+29%
2023
$18.7M
$38.6M
$4.9M
+61%
+26%
2022
$16.9M
$21.6M
$4.9M
+29%
+24%
2021
$16.1M
$20.4M
$3.9M
+18%
+26%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
5 insiders reported buying shares.
The record shows a net $10.0M bought by insiders over 180 days, 737 funds added last quarter, 2 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
BSX financials
Revenue growth
+19.9%
XBRL, annual
Net margin
14.4%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$21.0B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM BSX
| FY Dec 2025 | $20.1B |
| FY Dec 2024 | $16.7B |
| FY Dec 2023 | $14.2B |
| FY Dec 2022 | $12.7B |
| FY Dec 2021 | $11.9B |
| Jun 2026 | $5.4B |
| Mar 2026 | $5.2B |
| Dec 2025 | $5.3B |
| Sep 2025 | $5.1B |
| Jun 2025 | $5.1B |
| Mar 2025 | $4.7B |
| Dec 2024 | $4.6B |
| Sep 2024 | $4.2B |
At each fiscal year end
Single quarter
Net margin, TTM
+17.5%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM BSX
| FY Dec 2025 | +14.4% |
| FY Dec 2024 | +11.0% |
| FY Dec 2023 | +11.2% |
| FY Dec 2022 | +5.5% |
| FY Dec 2021 | +8.8% |
| Jun 2026 | +16.6% |
| Mar 2026 | +25.7% |
| Dec 2025 | +12.7% |
| Sep 2025 | +14.9% |
| Jun 2025 | +15.7% |
| Mar 2025 | +14.4% |
| Dec 2024 | +12.3% |
| Sep 2024 | +11.1% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$3.6B
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM BSX
| FY Dec 2025 | $3.7B |
| FY Dec 2024 | $2.6B |
| FY Dec 2023 | $1.8B |
| FY Dec 2022 | $938.0M |
| FY Dec 2021 | $1.3B |
| Jun 2026 | $1.3B |
| Mar 2026 | $171.0M |
| Dec 2025 | $1.0B |
| Sep 2025 | $1.2B |
| Jun 2025 | $1.1B |
| Mar 2025 | $354.0M |
| Dec 2024 | $1.2B |
| Sep 2024 | $823.0M |
At each fiscal year end
Single quarter
Debt to equity
0.51x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity BSX
| FY Dec 2025 | 0.47x |
| FY Dec 2024 | 0.49x |
| FY Dec 2023 | 0.47x |
| FY Dec 2022 | 0.51x |
| FY Dec 2021 | 0.55x |
| Jun 2026 | 0.51x |
| Mar 2026 | 0.43x |
| Dec 2025 | 0.47x |
| Sep 2025 | 0.50x |
| Jun 2025 | 0.52x |
| Mar 2025 | 0.51x |
| Dec 2024 | 0.49x |
| Sep 2024 | 0.53x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.36x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt BSX
| FY Dec 2025 | 0.40x |
| FY Dec 2024 | 0.32x |
| FY Dec 2023 | 0.27x |
| FY Dec 2022 | 0.17x |
| FY Dec 2021 | 0.21x |
| Jun 2026 | 0.36x |
| Mar 2026 | 0.39x |
| Dec 2025 | 0.40x |
| Sep 2025 | 0.40x |
| Jun 2025 | 0.37x |
| Mar 2025 | 0.34x |
| Dec 2024 | 0.32x |
| Sep 2024 | 0.27x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+15.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity BSX
| FY Dec 2025 | +12.6% |
| FY Dec 2024 | +9.0% |
| FY Dec 2023 | +8.6% |
| FY Dec 2022 | +4.1% |
| FY Dec 2021 | +6.5% |
| Jun 2026 | +15.5% |
| Mar 2026 | +14.8% |
| Dec 2025 | +12.6% |
| Sep 2025 | +12.6% |
| Jun 2025 | +11.7% |
| Mar 2025 | +9.6% |
| Dec 2024 | +9.0% |
| Sep 2024 | +9.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+8.5%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets BSX
| FY Dec 2025 | +7.0% |
| FY Dec 2024 | +5.0% |
| FY Dec 2023 | +4.7% |
| FY Dec 2022 | +2.2% |
| FY Dec 2021 | +3.3% |
| Jun 2026 | +8.5% |
| Mar 2026 | +8.4% |
| Dec 2025 | +7.0% |
| Sep 2025 | +6.9% |
| Jun 2025 | +6.3% |
| Mar 2025 | +5.3% |
| Dec 2024 | +5.0% |
| Sep 2024 | +5.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+11.0%
operating income after a 5.0% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital BSX
| FY Dec 2025 | +9.3% |
| FY Dec 2024 | +6.9% |
| FY Dec 2023 | +7.1% |
| FY Dec 2022 | +4.1% |
| FY Dec 2021 | n/a |
| Jun 2026 | +11.0% |
| Mar 2026 | +10.6% |
| Dec 2025 | +9.3% |
| Sep 2025 | +9.3% |
| Jun 2025 | +8.4% |
| Mar 2025 | +7.5% |
| Dec 2024 | +6.9% |
| Sep 2024 | +7.0% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+11.0%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed BSX
| FY Dec 2025 | +10.1% |
| FY Dec 2024 | +8.2% |
| FY Dec 2023 | +8.0% |
| FY Dec 2022 | +5.8% |
| FY Dec 2021 | +4.4% |
| Jun 2026 | +11.0% |
| Mar 2026 | +10.1% |
| Dec 2025 | +10.1% |
| Sep 2025 | +10.0% |
| Jun 2025 | +9.3% |
| Mar 2025 | +8.5% |
| Dec 2024 | +8.2% |
| Sep 2024 | +8.2% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
18.24x
close 2026-10-27 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing BSX
| FY Dec 2025 | 49.15x |
| FY Dec 2024 | 71.46x |
| FY Dec 2023 | 54.03x |
| FY Dec 2022 | 102.82x |
| FY Dec 2021 | 61.57x |
| Jun 2026 | 17.28x |
| Mar 2026 | 26.26x |
| Dec 2025 | 49.15x |
| Sep 2025 | 52.21x |
| Jun 2025 | 63.93x |
| Mar 2025 | 73.64x |
| Dec 2024 | 71.46x |
| Sep 2024 | 69.26x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$77.4B
market value at close 2026-10-27 on 2026-07-30 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2026-06-30
Enterprise value BSX
| FY Dec 2025 | $150.8B |
| FY Dec 2024 | $142.0B |
| FY Dec 2023 | $92.9B |
| FY Dec 2022 | $74.3B |
| FY Dec 2021 | $67.7B |
| Jun 2026 | $75.5B |
| Mar 2026 | $102.7B |
| Dec 2025 | $150.8B |
| Sep 2025 | $155.0B |
| Jun 2025 | $170.0B |
| Mar 2025 | $159.5B |
| Dec 2024 | $142.0B |
| Sep 2024 | $131.8B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+5.6%
TTM free cash flow over market value at close 2026-10-27
FCF yield BSX
| FY Dec 2025 | +2.6% |
| FY Dec 2024 | +2.0% |
| FY Dec 2023 | +2.1% |
| FY Dec 2022 | +1.4% |
| FY Dec 2021 | +2.2% |
| Jun 2026 | +5.7% |
| Mar 2026 | +3.7% |
| Dec 2025 | +2.6% |
| Sep 2025 | +2.6% |
| Jun 2025 | +2.2% |
| Mar 2025 | +2.0% |
| Dec 2024 | +2.0% |
| Sep 2024 | +1.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.39x
P/E over trailing EPS growth of 47%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing BSX
| FY Dec 2025 | 0.89x |
| FY Dec 2024 | 4.25x |
| FY Dec 2023 | 0.39x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | 0.37x |
| Mar 2026 | 0.35x |
| Dec 2025 | 0.89x |
| Sep 2025 | 0.96x |
| Jun 2025 | 1.75x |
| Mar 2025 | 4.87x |
| Dec 2024 | 4.25x |
| Sep 2024 | 1.46x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-27. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $20.1B | $16.7B | $14.2B | $12.7B |
| Gross profit | $13.9B | $11.5B | $9.9B | $8.7B |
| Operating income | $3.6B | $2.6B | $2.3B | $1.6B |
| Net income | $2.9B | $1.8B | $1.6B | $698.0M |
| EPS (diluted) | 1.94 | 1.25 | 1.07 | 0.45 |
| Operating cash flow | $4.5B | $3.4B | $2.5B | $1.5B |
| Cash | $2.0B | $414.0M | $865.0M | $928.0M |
| Long-term debt | $11.1B | $9.0B | $8.6B | $8.9B |
| Buybacks | n/a | n/a | n/a | $0 |
| Dividends paid | n/a | $0 | $28.0M | $55.0M |
SEC XBRL, fiscal years, as known on 2026-10-28
BSX Stock Sonar score 6/7 axes
Find similar shapesCompareBSX ranks highest on insider conviction (96th percentile) and profitability (74th), and lowest on risk and compliance (39th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
BSX filings, in plain words
Are Boston Scientific insiders buying or selling BSX?
In the 180 days to 2026-10-28, Boston Scientific insiders were net buyers, a net $10.0M across purchases and sales reported on Form 4, by 5 buyers.
Have members of Congress traded BSX?
Yes. In the year to 2026-10-28, 2 House members disclosed buying BSX and 3 House members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-09.
Read the full summary
In the 180 days to 2026-10-28, Boston Scientific insiders were net buyers of BSX, a net $10.0M across purchases and sales reported on Form 4 by 5 buyers. 4 different insiders reported purchases within the last 90 days, a cluster buy, which is rarer than a single purchase. In the year to 2026-10-28, 2 members of Congress disclosed buying BSX and 3 members disclosed selling it; the latest on record is a sale by Kevin Hern dated 2026-09-09. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
